

VIRALEZE™ partners with Harlequins in the UK

Melbourne, Australia; 11 May 2021: Starpharma (ASX: SPL, OTCQX: SPHRY) attaches a media release announcing the partnership between VIRALEZE™ and Harlequins in the UK, which was distributed today.

Harlequins is a professional English rugby union team, established in 1866, and one of the founding members of the Rugby Football Union. Harlequins play in the English Premiership, the top level of English rugby union. The Club's home ground is the Twickenham Stoop Stadium, "The Stoop", in south-west London.

For more information about Harlequins, visit www.quins.co.uk.

About Starpharma

Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) is a global biopharmaceutical company and a world leader in the development of new pharmaceutical and medical products based on proprietary polymers called dendrimers, with programs for COVID-19, DEP® drug delivery and VivaGel®. Starpharma has developed VIRALEZE™, an antiviral nasal spray for COVID-19, which is complementary to vaccines and other preventative measures such as distancing and PPE. VIRALEZE™ is registered for sale in the UK/Europe. VIRALEZE™ is available in the UK through LloydsPharmacy and in Europe via Starpharma's www.viraleze.co webstore. SPL7013 is utilised in approved products - the VivaGel® condom and VivaGel® BV. VivaGel® BV has been licensed in >160 countries, is approved in >45 countries and available for sale in the UK, Europe, Japan, South East Asia, Australia and New Zealand.

As a leading company in dendrimer-based drug delivery, Starpharma's proprietary drug delivery platform technology, DEP®, is being used to improve pharmaceuticals, to reduce toxicities and enhance their performance. There are numerous internal and partnered programs underway to develop DEP® versions of existing drugs, particularly in the area of anti-cancer therapies. DEP® partnerships include oncology programs with AstraZeneca, with Merck in the area of Antibody Drug Conjugates (ADCs), with Chase Sun in the area of anti-infectives and other world leading pharmaceutical companies. Starpharma's partnered DEP® programs have the potential to generate significant future milestones and royalties.

Starpharma.com | [Twitter](#) | [LinkedIn](#)

Media: Sumit Media

Grant Titmus
Mob: +61 419 388 161
grant@sumitmedia.com.au

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer
Nigel Baade, CFO and Company Secretary
+61 3 8532 2704
investor.relations@starpharma.com
4-6 Southampton Crescent
Abbotsford Vic 3067

Disclosure

This ASX Announcement was authorised for release by the Chairman, Mr Rob Thomas.



Forward Looking Statements

This document contains certain forward-looking statements, relating to Starpharma's business, which can be identified by the use of forward-looking terminology such as "promising", "plans", "anticipated", "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to", "potential", "seeking to", "goal", "could provide", "intends", "is being developed", "could be", "on track", or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected trial results, including additional analysis of existing data, and new data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. Starpharma is providing this information as of the date of this document and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise. Clinical case studies and other clinical information given in this document are given for illustrative purposes only and are not necessarily a guide to product performance and no representation or warranty is made by any person as to the likelihood of achievement or reasonableness of future results. Nothing contained in this document nor any information made available to you is, or shall be relied upon as, a promise, representation, warranty or guarantee as to the past, present or the future performance of any Starpharma product.



Harlequins

VIRALEZE

10 May 2021
MEDIA RELEASE
FOR IMMEDIATE RELEASE

Harlequins Take Next Step in Player COVID-19 Safety with VIRALEZE™ Antiviral Nasal Spray

Harlequins is delighted to partner with VIRALEZE™, an antiviral nasal spray that has been shown in laboratory studies to rapidly inactivate more than 99.9% of coronavirus/SARS-CoV-2.¹



Taking the next step in securing the safety of the Club's staff and players, Harlequins has partnered with VIRALEZE™, an antiviral nasal spray used to combat multiple strains of the virus that causes COVID-19.¹

Harlequins is the first Rugby Club in the UK to partner with [VIRALEZE™](#), which can be used in conjunction with other safety measures, helping to protect the Club's players and coaching staff.

¹ SSRN: <https://ssrn.com/abstract=3830085>

VIRALEZE™ also works against a broad spectrum of other respiratory viruses including common cold viruses, influenza, and RSV (respiratory syncytial virus).

Developed by leading biopharmaceutical company Starpharma, VIRALEZE™ is the only nasal spray containing a specifically designed antiviral active that has been shown in laboratory studies to irreversibly inactivate more than 99.9% of SARS-CoV-2 within one minute.¹

Harlequins' Head of Medical Services, Mike Lancaster, said the Quins were delighted to add VIRALEZE™ to the range of safety measures already in place to protect players from COVID-19.



“Player health is paramount in professional sport and now more than ever, we look to maximise the level of protection we can offer our players. The VIRALEZE™ partnership is an important additional level of protection for our Men’s and Women’s players against viruses such as flu and coronavirus/SARS-CoV-2.”

Starpharma’s CEO, Dr Jackie Fairley, said: “We are delighted to partner VIRALEZE™ with Harlequins, an iconic club with such a long and proud history.

“VIRALEZE™ is an ideal product for a team like the Quins, especially when the Club is playing away requiring team travel, as well as the close contact that is unavoidable in playing and training.

“We hope VIRALEZE™ brings the Club and its supporters’ greater confidence and peace of mind as they embark on the final matches of this season.”

VIRALEZE™ has been well received by consumers in the UK, following its launch on 30 March 2021 through the [LloydsPharmacy](https://www.lloydspharmacy.com) chain. It is also now available in Europe via the www.viraleze.co webstore.

The science behind VIRALEZE™

- VIRALEZE™ contains a specifically designed antiviral active that has been shown in laboratory studies to irreversibly inactivate more than 99.9% of coronavirus/SARS-CoV-2 within one minute of exposure.¹
- VIRALEZE™ works against multiple strains of SARS-CoV-2¹, as well as a broad spectrum of other respiratory viruses including common cold viruses, influenza, RSV, SARS, and MERS.
- VIRALEZE™ targets the nasal cavity, the primary site where the COVID-19/SARS-CoV-2 virus typically enters the body and can be used in conjunction with other safety measures.
- The active in VIRALEZE™, astodimer sodium, has been extensively studied in multiple viruses and is a component in products registered in more than 45 countries – including

the 27 countries of the EU, the UK, Japan, South East Asia, South Africa, Australia, and New Zealand.

- VIRALEZE™ contains an active that is not absorbed into the bloodstream and has been marketed in other products for more than seven years.
- VIRALEZE™ provides a moisturising and protective barrier to help keep nasal tissue hydrated.
- VIRALEZE™ is easy and convenient to use and can be stored at room temperature.

How it works

- VIRALEZE™ targets the area in the nasal cavity where respiratory viruses that cause colds, flu, and more severe respiratory illness, such as COVID-19, first attach and start to multiply.
- VIRALEZE™ contains astodimer sodium (SPL7013), which is antiviral and has been shown in laboratory studies to inactivate viruses¹, adding a further physical barrier to respiratory viruses.
- Astodimer sodium (SPL7013) acts by blocking the interaction between the SARS-CoV-2 viral 'spikes' and the human cells the virus is seeking to infect.

For more information on VIRALEZE™, visit www.viraleze.co.

For media enquiries:

Harlequins

Alistair Stokes

Communications Executive

Alistair.stokes@quins.co.uk

Starpharma

Catherine Devaney

WE Communications

Head of Health & Deputy Managing Director, UK

Viraleze@we-worldwide.com

+447788 444049

For Starpharma company enquiries:

Starpharma Holdings Limited

Dr Jackie Fairley, Chief Executive Officer

Nigel Baade, CFO and Company Secretary

Investor.relations@starpharma.com